Source link : https://www.newshealth.biz/health-news/study-supports-continued-use-of-cdk4-6-inhibitors-in-advanced-breast-cancer/
In a phase III trial presented at the American Society of Clinical Oncology annual meeting, researchers compared abemaciclib (Verzenio) plus fulvestrant (Faslodex) versus fulvestrant plus placebo in patients with hormone receptor-positive, HER2-negative advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy. In this exclusive MedPage Today video, Joanne Mortimer, MD, from […]
Author : News Health
Publish date : 2024-07-03 15:15:47
Copyright for syndicated content belongs to the linked Source.
Categories